Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Monitoring the introduction of pneumococcal conjugate vaccines into West Africa: design and implementation of a population-based surveillance system.

Mackenzie GA, Plumb ID, Sambou S, Saha D, Uchendu U, Akinsola B, Ikumapayi UN, Baldeh I, Usuf E, Touray K, Jasseh M, Howie SR, Wattiaux A, Lee E, Knoll MD, Levine OS, Greenwood BM, Adegbola RA, Hill PC.

PLoS Med. 2012 Jan;9(1):e1001161. doi: 10.1371/journal.pmed.1001161. Epub 2012 Jan 17.

2.

Effect of the introduction of pneumococcal conjugate vaccination on invasive pneumococcal disease in The Gambia: a population-based surveillance study.

Mackenzie GA, Hill PC, Jeffries DJ, Hossain I, Uchendu U, Ameh D, Ndiaye M, Adeyemi O, Pathirana J, Olatunji Y, Abatan B, Muhammad BS, Fombah AE, Saha D, Plumb I, Akano A, Ebruke B, Ideh RC, Kuti B, Githua P, Olutunde E, Ofordile O, Green E, Usuf E, Badji H, Ikumapayi UNA, Manjang A, Salaudeen R, Nsekpong ED, Jarju S, Antonio M, Sambou S, Ceesay L, Lowe-Jallow Y, Jasseh M, Mulholland K, Knoll M, Levine OS, Howie SR, Adegbola RA, Greenwood BM, Corrah T.

Lancet Infect Dis. 2016 Jun;16(6):703-711. doi: 10.1016/S1473-3099(16)00054-2. Epub 2016 Feb 18.

3.

Impact of the introduction of pneumococcal conjugate vaccination on pneumonia in The Gambia: population-based surveillance and case-control studies.

Mackenzie GA, Hill PC, Sahito SM, Jeffries DJ, Hossain I, Bottomley C, Uchendu U, Ameh D, Ndiaye M, Osuorah CD, Adeyemi O, Pathirana J, Olatunji Y, Abatan B, Ahameefula E, Muhammad BS, Fombah AE, Saha D, Mackenzie R, Plumb I, Akano A, Ebruke B, Ideh RC, Kuti B, Githua P, Olutunde E, Ofordile O, Green E, Usuf E, Badji H, Ikumapayi UNA, Manjang A, Salaudeen R, Nsekpong ED, Jarju S, Antonio M, Sambou S, Ceesay L, Lowe-Jallow Y, Sowe D, Jasseh M, Mulholland K, Knoll M, Levine OS, Howie SR, Adegbola RA, Greenwood BM, Corrah T.

Lancet Infect Dis. 2017 Sep;17(9):965-973. doi: 10.1016/S1473-3099(17)30321-3. Epub 2017 Jun 7.

4.

Economic evaluation of pneumococcal conjugate vaccination in The Gambia.

Kim SY, Lee G, Goldie SJ.

BMC Infect Dis. 2010 Sep 3;10:260. doi: 10.1186/1471-2334-10-260.

5.

Assessing the impact of pneumococcal conjugate vaccines on invasive pneumococcal disease using polymerase chain reaction-based surveillance: an experience from South Africa.

Tempia S, Wolter N, Cohen C, Walaza S, von Mollendorf C, Cohen AL, Moyes J, de Gouveia L, Nzenze S, Treurnicht F, Venter M, Groome MJ, Madhi SA, von Gottberg A.

BMC Infect Dis. 2015 Oct 26;15:450. doi: 10.1186/s12879-015-1198-z.

6.

Pneumococcal conjugate vaccine--a health priority.

Zar HJ, Madhi SA.

S Afr Med J. 2008 Jun;98(6):463-7.

PMID:
18683380
7.

Imputing the Direct and Indirect Effectiveness of Childhood Pneumococcal Conjugate Vaccine Against Invasive Pneumococcal Disease by Surveying Temporal Changes in Nasopharyngeal Pneumococcal Colonization.

Nzenze SA, Madhi SA, Shiri T, Klugman KP, de Gouveia L, Moore DP, Karstaedt AS, Tempia S, Nunes MC, von Gottberg A.

Am J Epidemiol. 2017 Aug 15;186(4):435-444. doi: 10.1093/aje/kwx048.

PMID:
28482004
8.

Evaluating the impact of PCV-10 on invasive pneumococcal disease in Brazil: A time-series analysis.

Andrade AL, Minamisava R, Policena G, Cristo EB, Domingues CM, de Cunto Brandileone MC, Almeida SC, Toscano CM, Bierrenbach AL.

Hum Vaccin Immunother. 2016;12(2):285-92. doi: 10.1080/21645515.2015.1117713.

9.

HIV Infection and the Epidemiology of Invasive Pneumococcal Disease (IPD) in South African Adults and Older Children Prior to the Introduction of a Pneumococcal Conjugate Vaccine (PCV).

Meiring S, Cohen C, Quan V, de Gouveia L, Feldman C, Karstaedt A, Klugman KP, Madhi SA, Rabie H, Sriruttan C, von Gottberg A; GERMS-SA.

PLoS One. 2016 Feb 10;11(2):e0149104. doi: 10.1371/journal.pone.0149104. eCollection 2016.

10.

Pneumococcal serotype evolution in Western Europe.

Tin Tin Htar M, Christopoulou D, Schmitt HJ.

BMC Infect Dis. 2015 Oct 14;15:419. doi: 10.1186/s12879-015-1147-x. Review.

11.

Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway.

Steens A, Bergsaker MA, Aaberge IS, Rønning K, Vestrheim DF.

Vaccine. 2013 Dec 16;31(52):6232-8. doi: 10.1016/j.vaccine.2013.10.032. Epub 2013 Oct 29.

PMID:
24176490
12.

Invasive pneumococcal disease among children younger than 5 years of age before and after introduction of pneumococcal conjugate vaccine in Casablanca, Morocco.

Diawara I, Zerouali K, Katfy K, Zaki B, Belabbes H, Najib J, Elmdaghri N.

Int J Infect Dis. 2015 Nov;40:95-101. doi: 10.1016/j.ijid.2015.09.019. Epub 2015 Oct 3.

13.

Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites.

Feikin DR, Kagucia EW, Loo JD, Link-Gelles R, Puhan MA, Cherian T, Levine OS, Whitney CG, O'Brien KL, Moore MR; Serotype Replacement Study Group.

PLoS Med. 2013;10(9):e1001517. doi: 10.1371/journal.pmed.1001517. Epub 2013 Sep 24.

14.

Impact of pneumococcal conjugate vaccines on nasopharyngeal carriage and invasive disease among unvaccinated people: review of evidence on indirect effects.

Davis SM, Deloria-Knoll M, Kassa HT, O'Brien KL.

Vaccine. 2013 Dec 17;32(1):133-45. doi: 10.1016/j.vaccine.2013.05.005. Epub 2013 May 16. Review.

PMID:
23684824
15.

The worldwide impact of the seven-valent pneumococcal conjugate vaccine.

Fitzwater SP, Chandran A, Santosham M, Johnson HL.

Pediatr Infect Dis J. 2012 May;31(5):501-8. doi: 10.1097/INF.0b013e31824de9f6.

PMID:
22327872
16.

Experience with pneumococcal polysaccharide conjugate vaccine (conjugated to CRM197 carrier protein) in children and adults.

Durando P, Faust SN, Fletcher M, Krizova P, Torres A, Welte T.

Clin Microbiol Infect. 2013 Oct;19 Suppl 1:1-9. doi: 10.1111/1469-0691.12320. Review.

17.

The potential impact of pneumococcal conjugate vaccine in Africa: Considerations and early lessons learned from the South African experience.

Madhi SA, Nunes MC.

Hum Vaccin Immunother. 2016;12(2):314-25. doi: 10.1080/21645515.2015.1084450. Review.

18.

Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines.

Tyo KR, Rosen MM, Zeng W, Yap M, Pwee KH, Ang LW, Shepard DS.

Vaccine. 2011 Sep 2;29(38):6686-94. doi: 10.1016/j.vaccine.2011.06.091. Epub 2011 Jul 13.

PMID:
21745516
19.

Invasive pneumococcal disease in Catalonian elderly people, 2002-2009: serotype coverage for different anti-pneumococcal vaccine formulations at the beginning of the new conjugate vaccines era.

Vila-Corcoles A, Ochoa-Gondar O, Gomez-Bertomeu F, Raga-Luria X; EPIVAC Study Group.

Vaccine. 2011 Oct 6;29(43):7430-4. doi: 10.1016/j.vaccine.2011.07.066. Epub 2011 Jul 29.

PMID:
21803108
20.

Serotype distribution of Streptococcus pneumoniae causing invasive disease in children in the post-PCV era: A systematic review and meta-analysis.

Balsells E, Guillot L, Nair H, Kyaw MH.

PLoS One. 2017 May 9;12(5):e0177113. doi: 10.1371/journal.pone.0177113. eCollection 2017. Review.

Supplemental Content

Support Center